GlassScriptPhysician profile
Allison Boonie
NPI 1174948384
$8,434.13
in general payments reported to CMS, 2019-2025
62 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,535 · 2022: $1,405 · 2023: $1,749 · 2024: $2,150 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,493.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,137.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,062.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $866.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $598.57 | 2021-2025 | |
| Lilly USA, LLC | $429.38 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.11 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $244.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $234.51 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.83 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $193.79 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $177.91 | 2021-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $173.08 | 2022-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.84 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $146.42 | 2021-2024 | Veozah |
| Amgen INC. | $132.31 | 2021-2024 | Otezla, Repatha |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Boonie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.